- Home
- PTGX vs GRFS Comparison
PTGX vs GRFS Comparison
Compare PTGX & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PTGX | GRFS |
|---|---|---|
| Founded | 2006 | 1940 |
| Country | United States | Spain |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 6.0B |
| IPO Year | 2016 | 2006 |
Fundamental Metrics
Financial Performance| Metric | PTGX | GRFS |
|---|---|---|
| Price | $89.29 | $8.88 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 1 |
| Target Price | ★ $86.44 | $10.30 |
| AVG Volume (30 Days) | ★ 886.1K | 610.0K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 1.61% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.72 | 0.64 |
| Revenue | $209,217,000.00 | ★ $8,821,017,248.00 |
| Revenue This Year | N/A | $5.46 |
| Revenue Next Year | $296.47 | $5.60 |
| P/E Ratio | $124.09 | ★ $17.37 |
| Revenue Growth | N/A | ★ 7.31 |
| 52 Week Low | $33.70 | $6.19 |
| 52 Week High | $93.25 | $11.14 |
Technical Indicators
Market Signals| Indicator | PTGX | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 64.67 | 50.78 |
| Support Level | $83.52 | $7.64 |
| Resistance Level | $90.85 | $9.02 |
| Average True Range (ATR) | 2.63 | 0.27 |
| MACD | -0.33 | 0.07 |
| Stochastic Oscillator | 83.62 | 88.36 |
Price Performance
Historical ComparisonAbout PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
About GRFS Grifols S.A.
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.